ep pro-forma
basi divestitur portion
investor analyst meet takeaway
institut investor analyst meet manag laid long-term
financi target updat pipelin cost save initi emerg
market opportun l-t target sales/ep growth plu dividend
current yield believ build conservat incorpor
potenti modest fx volatil near term believ initi sale
guidanc provid call also look conserv consid trend
come repatri cash also provid dri powder liquid
ou asset next quarter robot timelin push-out
disappoint surpris given previou commentari repres
signific long-term tam-expand along mitral valv replac renal
sale target long-rang organ cc growth sale target compris
growth develop low-double-digit growth emerg market
divis guidanc assum cvg mitg rtg growth in-lin corpor
averag plan period diabet tuck-in upsid
cash access post-tax reform target increas convers
oper expansion/sharehold return recent initi
enterpris excel initi expect achiev annual
network optim share servic increas autom
commerci busi target gross run-rat save
reiter commit return least sharehold
estim forecast sales/ep growth pro forma sale
guidanc believ look conserv follow growth fx
tailwind ep tweak ep
slightli lower margin assumpt though still see newli freed-up
ou cash potenti upsid estim
new cvg near/medium-term driver peg weight averag market
growth within cvg next two year manag
highlight evolut launch risk data expect
tavr continu indic expans micra leadless pacemak rise
elig market applic today next-gener
long-term cvg driver includ ramp low-risk tavr market tavr system
iter extravascular first chronic implant smaller mvad
system lvad market admir dcb below-the-kne renal denerv
transcathet mitral valv replac latter two
develop manufactur
devic treatment cardiovascular
spinal ent condit
neurolog gastroenterolog
analyst certif import disclosur see disclosur
mid-singl digit underli sale growth led combin new
product flow emerg market growth
continu return free cash flow least investor
modest use
announc march
see sever sale driver ahead includ new
lvad geograph emerg
footprint reduct drive cash ep growth use
newli freed-up ou cash potenti upsid
use repatri cash
use free cash flow and/or enhanc buyback
upsid pipelin time
quicker launch robot system
price pressur core market increas
target price driven discount cash flow analysi weight averag cost capit termin growth
estim ebitda target price impli calendar cash ep estim
risk price target includ limit macro headwind pipelin failur price payor pressur competit
domin market
rtg highlight manag see weight averag market growth wamgr rtg
divis note grow momentum past two year includ
growth manag also highlight build traction mazor robot partnership
expect core spine biolog enabl technolog portfolio acceler
mid-single-digit come year mazor integr stealthstat navig
later neuromodul on-going launch intelli system evolv workflow
identifi algorithm stimul appropri suit individu patient need
acceler pain therapi neurovascular remain strong led solitair stent ischem
stroke pipelin flow divers aneurysm therapi
mitg wamgr mitg accord expect grow mid-singl
digit led largest growth contributoradvanc minim invas surgeri mi well
meaning contribut emerg market today mitg driven solid surgic
innov growth led advanc stapl advanc energi system robot surgeri key
medium/long term pipelin initi focu shift open surgeri mi continu though
open surgeri still repres total procedur tradit mi procedur account
total procedur robotic-assist procedur mani detail robot system
provid though address cost barrier one clear messag along make
system versatil flexibl abil procedur compani plan advanc
system clinic broader set surgeon goal launch
initi launch reveal compani dialogu fda
diabet expect grow diabet busi corpor averag compani see
opportun cgm sensor pull-through result hybrid-clos loop system
cgm attach rate instal insulin pump base see attach rate
patient come warranti renew drive increas
annual per patient revenu new technolog also potenti acceler
penetr insulin pump market type patient popul stand
us less take account type ii patient multipl daili inject also
enter acceler stand-alon cgm market recent approv guardian sensor
predict alert one key featur highlight manag new sensor
long-term cvg pipelin mitral valv replac market opportun
mitral valv signific incid sever mitral regurgit aortic stenosi
yet space lack effect treatment see potenti repair replac market
year initi target tmv replac believ major
market long-term apollo trial first trial mitral valv replac enrol well
activ site target first-in-human implant transfemor tran septal version
system renal denerv treatment resist hypertens signific
opportun billion patient hypertens world-wide today follow initi pivot trial
failur made sever chang renal denerv program includ chang locat
ablat chang cathet design chang patient popul focu
systol diastol hypertens final better control monitor adjunct
drug therapi success pilot trial on-med off-med set
patient enrol pivot trial patient take medic underway expect
complet year compani plan build evid base clinic econom data
use reimburs anticip fda approv beyond
free compani laid near-term year convers target
peg peer averag convers past three
year averag includ improv driven inventori
optim reduct one-tim item well work capit effici align
corpor object made modif employe incent plan correl portion
specif target rather work capit cash flow indic annual incent plan
metric revenu ep remind tax reform increas access
world-wide cash debt paydown longer top prioriti tuck-in like
take promin near-term use cash also freed trap cash
balanc sheet result tax reform actual repatri previous trap ou cash
occur liquid ou asset next sever quarter
net loss attribut non-controlling interest
